Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O'Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, Ruhwald M, de Visser AW, Agger EM, Ottenhoff TH, Kromann I, Andersen P. van Dissel JT, et al. Among authors: thierry carstensen b. Vaccine. 2014 Dec 12;32(52):7098-107. doi: 10.1016/j.vaccine.2014.10.036. Epub 2014 Oct 30. Vaccine. 2014. PMID: 25454872 Free article. Clinical Trial.
A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B, Jordan K, Uhlving HH, Dalby T, Sørensen C, Jensen AM, Heilmann C. Thierry-Carstensen B, et al. Vaccine. 2012 Aug 10;30(37):5464-71. doi: 10.1016/j.vaccine.2012.06.073. Epub 2012 Jul 6. Vaccine. 2012. PMID: 22776216 Clinical Trial.
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Thierry-Carstensen B, Dalby T, Stevner MA, Robbins JB, Schneerson R, Trollfors B. Thierry-Carstensen B, et al. Vaccine. 2013 Oct 25;31(45):5178-91. doi: 10.1016/j.vaccine.2013.08.034. Epub 2013 Aug 28. Vaccine. 2013. PMID: 23994021 Free article. Review.
First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Lindgren LM, Tingskov PN, Justesen AH, Nedergaard BS, Olsen KJ, Andreasen LV, Kromann I, Sørensen C, Dietrich J, Thierry-Carstensen B. Lindgren LM, et al. Among authors: thierry carstensen b. Vaccine. 2017 Jan 23;35(4):596-604. doi: 10.1016/j.vaccine.2016.12.027. Epub 2016 Dec 24. Vaccine. 2017. PMID: 28027810 Free PMC article. Clinical Trial.
Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months.
Sáez-Llorens X, Thierry-Carstensen B, Stoey LS, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV. Sáez-Llorens X, et al. Among authors: thierry carstensen b. Vaccine. 2020 May 6;38(21):3780-3789. doi: 10.1016/j.vaccine.2020.02.066. Epub 2020 Apr 6. Vaccine. 2020. PMID: 32273184 Free PMC article. Clinical Trial.
Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.
Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora CFCB, Thierry-Carstensen B, Tingskov PN, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV. Bravo LC, et al. Among authors: thierry carstensen b. Vaccine. 2020 Jan 16;38(3):530-538. doi: 10.1016/j.vaccine.2019.10.064. Epub 2019 Nov 5. Vaccine. 2020. PMID: 31703934 Free PMC article. Clinical Trial.
Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique.
Lillebaek T, Bergstedt W, Tingskov PN, Thierry-Carstensen B, Aggerbeck H, Hoff ST, Weldingh K, Andersen P, Soborg B, Thomsen VO, Andersen AB. Lillebaek T, et al. Among authors: thierry carstensen b. Tuberculosis (Edinb). 2009 Mar;89(2):158-62. doi: 10.1016/j.tube.2008.09.007. Epub 2009 Feb 8. Tuberculosis (Edinb). 2009. PMID: 19208500 Clinical Trial.
15 results